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T o manage chronic disease patients effectively, clinicians must know (i) how to monitor each patient (i.e., when toschedule the next visit and which tests to take), and (ii) how to control the disease (i.e., what levels of controllable
risk factors will sufficiently slow progression). Our research addresses these questions simultaneously and provides the
optimal solution to a novel linear quadratic Gaussian state space model. For the objective of minimizing the relative
change in state over time (i.e., disease progression), which is necessary for managing irreversible chronic diseases while
also considering the cost of tests and treatment, we show that the classical two-way separation of estimation and control
holds. This makes a previously intractable problem solvable by decomposition into two separate, tractable problems while
maintaining optimality. The resulting optimization is applied to the management of glaucoma. Based on data from two
large randomized clinical trials, we validate our model and demonstrate how our decision support tool can provide
actionable insights to the clinician caring for a patient with glaucoma. This methodology can be applied to a broad range
of irreversible chronic diseases to devise patient-specific monitoring and treatment plans optimally.
Key words: chronic disease monitoring and treatment; personalized care; medical decision making; glaucoma; Kalman filter
History: Received: February 2016; Accepted: October 2018 by Sergei Savin, after 3 revisions.
1. Introduction
Chronic diseases are the leading cause of both death
and disability and affect almost one out of every
two adults in the United States (Ward et al. 2014).
To manage chronic diseases, patients are tested
quantitatively at prescribed intervals using a
selected set of testing modalities to assess disease
progression and decide whether a change in treat-
ment is warranted. In this context, proper testing
and treatment guidance is critical to both cost con-
tainment and patient outcomes in the management
of chronic diseases. In this study, we develop a
modeling framework for dynamic management of
irreversible chronic diseases that enables us to (i)
specify the optimal timing of each office visit and
the appropriate suite of tests (i.e., the selection of
testing modalities) to perform at that visit consider-
ing the costs and value of each test and the uncer-
tainty about the patient’s disease progression
(disease monitoring), and (ii) identify optimal target
levels for controllable disease risk factors to slow the
rate of disease progression without over-treating or
under-treating the patient (treatment control).
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To do so, we introduce and solve a new type of
objective function for linear quadratic Gaussian (LQG)
systems that minimizes the relative change in state (i.e.,
disease progression) rather than the traditional objec-
tive of minimizing the cost of being in each state, while
still accounting for the test and treatment costs as in the
traditional objective. We extend LQG theory by prov-
ing that the classical two-way separation of optimal
state estimation and control applies to this new objec-
tive. This separation ensures computational tractability
for the simultaneous optimization of disease monitor-
ing and treatment control. This innovative modeling of
dynamic disease monitoring and treatment control is
developed to be applicable to many irreversible chronic
diseases. As a proof of concept, we demonstrate the
capabilities of this methodology by applying it to glau-
coma, a chronic disease causing progressive blindness.
1.1. Scope of the Research
It is important to distinguish the disease monitoring
problem from screening for a disease. The goal of dis-
ease screening is to determine whether or not a
patient has a particular disease. A screening test is
taken when the patient is considered to be at some
risk of developing a condition but exhibits no symp-
toms of the illness. For the disease monitoring prob-
lem, however, the patient is already known to have
the disease, and the goal is to detect the presence of
disease progression quickly and identify whether/
how to adjust the treatment plan to slow/avert fur-
ther disease progression.
For the treatment control portion of the problem,
the goal is to determine the time-dependent intensity
of treatment over a treatment cycle based on dynami-
cally updating information on patient disease state
from the monitoring portion.
We emphasize that our model does not suggest a
specific intervention. Rather, it provides patient-spe-
cific target levels for controllable/modifiable disease
risk factors that help guide the doctor in selecting an
appropriate treatment plan for the patient. Though
one might try to model how each intervention affects
the disease progression dynamics, we feel it is best to
leave it to the clinician to employ his/her experience
and expertise to decide what therapeutic interven-
tions are most likely able to achieve the target levels
suggested by our model.
1.2. Main Contributions
• Theory: (1) To the best of our knowledge, this is
the first research paper to employ measurement
adaptive systems theory to the monitoring and
control of chronic diseases (or even to any health-
care operations research problem), and this new
application requires an extension of the underly-
ing theory. We extend the LQG state space
modeling literature by introducing a new objec-
tive that minimizes the relative change in system
state over time (i.e., the difference in estimated
state elements between the current period and
the previous period), rather than minimizing the
cost of current state, while still considering the
cost of tests and treatment. In prior applications
of LQG modeling to other engineering problems,
the goal of the controller has been to keep the
system state on a static desired trajectory using
costly control actions by minimizing the devia-
tion of the current system position from the
desired trajectory over time. However, in irre-
versible diseases such as glaucoma, once the dis-
ease has progressed, it is biologically impossible
to reverse the damage. In this context, the
desired trajectory is to maintain the “current dis-
ease state position” (i.e., stop the disease from
worsening), which the model updates dynami-
cally as the disease progresses over time. This
necessitates a new structure for the objective
function (Equation 3) not yet studied in LQG lit-
erature.
(2) For LQG systems theory, the two-way separa-
tion of optimal state estimation and control
(known as the separation principle) has been a criti-
cal foundation upon which to optimize estimation
and control of probabilistic systems tractably and
simultaneously (see Witsenhausen 1971). Our
main theoretical results show that the two-way
separation of optimal estimation and control
extends to this new objective of relative system
state change, which involves two correlated state
variables from the current and previous time peri-
ods. The treatment control can be optimized in
closed form as a linear function of the best esti-
mate of the patient’s current disease state (i.e., fil-
tered state mean given by the Kalman filter) via
completion of squares. Furthermore, we show
that the monitoring problem can be reduced to a
continuous-state discrete-action Markov decision
process (MDP) model with filtered and smoothed
covariance matrices of the state serving as the
information state and the Kalman filter and
smoother equations acting as the system dynam-
ics. The MDP can be solved via dynamic pro-
gramming to find the optimal monitoring
schedule specific to each individual patient.
(3) A Kalman filter and smoother are built into
our modeling framework to extract noise from the
raw measurements and to estimate the disease
state optimally in each time period based on
imperfect/noisy measurements. This is key to
accurately identifying genuine disease progression
from testing artifacts. The Kalman smoother is a
new feature in our model (compared with the
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traditional LQG models), and it is essential
because of the new objective function we employ.
State smoothing means using information gained
at time t to update the prior estimate made at t1
of the value of the state at t1. Filtering refers to
estimating the current disease state based on new
test results.
• Application: (1) We develop an integrated, feed-
back-driven stochastic control model to provide
the jointly optimal solution to both the disease
monitoring and treatment control problems. Note
that the monitoring regime affects the disease
control problem. As new tests are performed, the
information gained can affect how the doctor
controls/slows the progression of the disease.
Therefore, it is critical to model and solve the dis-
ease monitoring and control problems together to
capture the interaction between them.
(2) The model explicitly determines which suite of
tests to take at each time period. Some tests are
significantly easier and cheaper to perform than
others. Different tests may provide more or less
information about the patient’s disease state.
Therefore, it is important to be able to differentiate
which tests to perform at each time point in terms
of improved monitoring and cost containment.
(3) We develop a data-driven decision support
tool that provides a menu of options to the doctor
based on how aggressively he/she wants to
monitor and control the patient. The doctor can
select an appropriate aggressiveness option
depending on the patient’s life expectancy, sever-
ity of disease, and other personal and clinical fac-
tors. For each aggressiveness option, the model
incorporates new and past test results as well as
clinically-believed and data-verified disease
dynamics to predict and graph the future disease
trajectory and recommend a patient-specific
monitoring regime and target level for control-
lable disease risk factors.
• Data: (1) We parametrize and validate our model
using data from two landmark randomized clini-
cal trials of patients with glaucoma. Our numeri-
cal results indicate that the model achieves low
errors in predicting the future disease trajectory.
(2) The results suggest the potential to improve
both patient outcomes and system cost when
applied to patients from the clinical trial already
receiving a high level of care. This potential is
likely greater for patients being treated by non-
glaucoma specialists.
2. Literature Review
Papers relevant to this research are classified into
three categories: (i) theoretical papers on
measurement adaptive systems and sensor schedul-
ing, (ii) medical decision making papers on disease
screening, diagnosis, and monitoring, and (iii) opti-
mization models on treatment planning and disease
control. In this section, we highlight some prominent
papers in each category and briefly describe how our
research methodologies and objectives are different.
Measurement adaptive systems and sensor scheduling:
The closest paper to our work in terms of theory is
Meier et al. (1967). This study lays the foundations for
measurement adaptive systems in which the controller
seeks to keep the system state on a static desired trajec-
tory and obtain information about the system state
simultaneously with minimum total cost over a finite
horizon. They show that, in the special case of discrete-
time systems, linear system dynamics, quadratic cost
of the current state, and Gaussian random noise pro-
cesses, the problem of finding the optimal measure-
ment policy reduces to the solution of a nonlinear,
deterministic control problem. Baron and Kleinman
(1969) extend their work to continuous-time measure-
ments and investigate the optimal measurement dura-
tion for a human operator. Bansal and Basar (1989)
provide an extension of this framework to the infinite-
horizon setting with discounted costs. Our work dif-
fers in that it deals with a dynamic desired trajectory,
minimizing the relative change in state in each time
period (i.e., disease progression), which is essential for
managing irreversible chronic diseases (as discussed
in subsection 1.2). For example, experiments using the
model provided by Meier et al. (1967) led to results
considered clinically incorrect/unbelievable in the
experience of our clinical co-author, a glaucoma spe-
cialist. We discuss this more in section 3.3.
There is also extensive literature on sensor schedul-
ing problems, in which a set of sensors is used to esti-
mate a stochastic process, but because of cost or
design constraints, only one or a subset of them takes
measurements at each time point. Athans (1972) con-
siders the problem in which the controller has to
select one measurement provided by one sensor out
of many available sensors (with different measure-
ment costs) at each time step, such that a weighted
combination of prediction accuracy and accumulated
observation cost is minimized. Examples of other
work in this area include Gupta et al. (2006), Mehra
(1976), and Vitus et al. (2012). However, these papers
differ from ours in that they do not consider the trade-
off between exploration vs. exploitation.
Disease screening, diagnosis, and monitoring: While
there is extensive literature on disease screening and
diagnosis problems, there is relatively little work on
the disease monitoring problem that we defined in
section 1.1. Helm et al. (2015) and Schell et al. (2014)
provide a heuristic approach for finding the time in
between tests based on patient’s probability of
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progression. Note that their work focuses only on the
timing of the next test and does not consider how that
test would impact future tests performed nor the type
of test performed at each visit. (They assume all of the
tests are performed at each office visit.) These works
also do not incorporate optimization of controllable
disease risk factors (i.e., treatment planning), which is
a key factor to consider when managing patients with
chronic diseases. Ayer et al. (2012) provide a partially
observable Markov decision process (POMDP)
approach to personalize mammography screening
decisions; their work is based on the prior screening
history and personal risk characteristics of women.
Chhatwal et al. (2010) develop a finite-horizon dis-
crete-time Markov decision process (MDP) model to
help radiologists determine the best time for a biopsy
based on the initial mammography findings and
patient demographics. Their goal is to maximize a
patient’s total expected quality-adjusted life years.
The works of Yang et al. (2013), Mangasarian et al.
(1995), Saaty and Vargas (1998), Zhang et al. (2012),
Lee et al. (2019), and Erenay et al. (2014) are other
examples of disease screening models. These works
differ from ours in that they focus on the screening
problem where the goal is to detect the presence of a
particular disease with minimum delay. They do not
provide any insights into how to monitor the patient
if the presence of the disease is confirmed and pro-
gression trajectory can be monitored over time, nor
do they consider treatment planning. Kreke (2007)
develops a POMDP model to study the question of
when to test for cytokine levels in patients with sepsis
using available, costly, and inaccurate tests. Suen
et al. (2017) develop a POMDP framework to deter-
mine when and how often sputum smear test infor-
mation should be collected from patients on first-line
treatment of tuberculosis and use this information to
find the optimal time to administer drug sensitivity
testing. These works consider the problem of timing
of each test with testing noise and system noise but
do not consider simultaneous disease monitoring and
treatment decisions.
Treatment planning and disease control: There has been
a variety of work considering when to start treatment
of a patient when the presence of disease is confirmed
(also known as surveillance problems). Lavieri et al.
(2012) develop a Kalman filter-based approach to help
clinicians decide when to start radiation therapy in
patients with prostate cancer based on predictions of
the time when the patient’s prostate specific antigen
(PSA) level reaches its lowest point. Notice that, differ-
ent from our approach, its actions are discrete (start/
do not start radiation therapy) rather than establishing
the level of therapy to be given. Furthermore, this
work did not consider when the patient should be
monitored, assuming the patient would be seen at the
clinic once a month. Shechter et al. (2008) employ Mar-
kov decision processes (MDP) to optimize the time to
initiate HIV treatment to maximize a patient’s quality-
adjusted life years. Mason et al. (2014) and Schell et al.
(2019) present MDP models to determine the optimal
timing of blood pressure and cholesterol medications.
All of these papers assume a measurement of the
patient’s health is taken periodically. Our work differs
in that it solves the joint problem of optimal timing of
each test and optimal treatment control.
Moreover, in most of the previous research men-
tioned, the patient’s disease dynamics are assumed to
be known or are estimated using population-based
models. In our model, the population data is inte-
grated with individual patient measurements gath-
ered from sequential testing so that the predictions
and decisions made are unique to each patient. Cap-
turing the complex patient disease dynamics requires
incorporating several health indices into the state vec-
tor. We employ a continuous state space that easily
accommodates multivariate states (e.g., nine dimen-
sions in our model for glaucoma) and provide jointly
optimal solutions to both disease monitoring and con-
trol problems. Employing a continuous state space
model is important as many quantitative tests for dis-
ease monitoring are continuous. Problems with such
a multivariate, continuous state-space often become
intractable for MDP-based approaches due to the
curse of dimensionality. Discretization of the state
space and using approximate dynamic programming
(ADP) to mitigate the curse of dimensionality of MDP
models is an alternative approach when our modeling
framework does not fit. For example, strongly discrete
state variables, highly nonlinear disease dynamics,
and highly non-Gaussian random noises are features
that are difficult for our model to handle. However, it
should be noted that discretization of the state space
and grouping discrete states together to reduce the
model size is shown to reduce the predictive power of
the MDP models as a result of lumping error (see Reg-
nier and Shechter 2013). The implication is that if the
assumptions in our model are reasonable for a dis-
ease, a modeling framework like what we present in
this study that can accommodate continuous state
space (for a disease with continuous variables) with-
out loss of optimality can benefit from more accurate
predictions (specially beyond one period into the
future) and can be solved tractably.
3. The Modeling Framework
A continuous state space model is employed at the
heart of our modeling framework with two key com-
ponents: (i) a state transition process to model disease
progression dynamics, and (ii) a measurement/test-
ing process to model how the true disease state is
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observed. Both processes (Equations 1 and 2) are in
the form of first-order (linear) vector difference equa-
tions with additive Gaussian white noise (i.e., noise
inputs at time t and t
0
are independent). The objective
function seeks to minimize the weighted sum of multi-
ple cost elements with state independent cost parame-
ters/weights. The optimization problem determines
both the optimal disease control (how to control modi-
fiable risk factors) and the optimal monitoring (when
to take new measurements), both of which are patient-
specific and state-dependent. Such a model can be a
good fit for many chronic diseases (such as glaucoma)
since the measurements are typically on a continuous
scale. In the case study of glaucoma (section 5), we will
elaborate on how we adjust for some of the model
assumptions, for example, we include first and second-
order derivatives of key disease state elements in the
state vector to capture some degree of nonlinearity in
our linear model, and we define various aggressive-
ness levels that the clinician can choose from, each of
which is tied to a set of cost parameters.
3.1. State Transition Process
The recursive state transition equation for our N-stage
time horizon is given by
atþ1 ¼ Ttat þ Gtbt þ gt; t ¼ 1; . . .;N; ð1Þ
where at is the random vector representing the state
of the disease at time t, bt is the “disease control”
variable administered at time t, gt is the vector of
Gaussian white noise that represents unmodeled dis-
ease process noise with E[gt] = 0 and Cov(gt) = Qt, Tt
is the state transition matrix governing the underlying
disease progression dynamics, and Gt is a vector cap-
turing the effect of disease control variable bt on the
next period state, at+1. bt is one of the two optimiza-
tion variables of the model. It determines how the
modifiable disease risk factors should be adjusted at
time t to slow the progression of disease optimally.
Our model seeks to adjust the modifiable risk factors
in the first few time periods, after which bt converges
to zero. By summing the total amount of control bt
over this timeframe, we obtain a target level for each
modifiable risk factor. We will illustrate this in section
5.8.2. Having such information will help clinicians
select the appropriate treatment plan for the patient.
3.2. Measurement/Testing Process
The measurement equation gives the relationship
between the true disease state, at, and the noisy raw
reading/observation, zt, as follows.
zt ¼ Ztat þ et; t ¼ 1; . . .;N; ð2Þ
where zt is the observation vector (i.e., the result of
test(s) performed on the patient), Zt is the
observation matrix and determines how components
of the true state are observed, and ɛt is the multi-
variate Gaussian white test noise with [ɛt] = 0 and
CovðetÞ ¼ HðhtÞt . ht is the “test/measurement con-
trol” variable that determines which subset of tests
to take in period t; it is the other control variable
the model optimizes. H
ðhtÞ
t models the error associ-
ated with the tests and is directly affected by the
decision on which test(s) to take at time t (which we
highlight by adding ðhtÞ to the superscript, that is,
H
ðhtÞ
t ). It is worth noting that both at+1 and zt are
Gaussian random vectors since they are a linear
combination of independent Gaussian random vari-
ables. The initial state, a0, is Gaussian with
E½a0 ¼ a^0 ¼ a^1j0 and Covða0Þ ¼ R^0 ¼ R^1j0. The
random variables a0, {gt}, and {ɛt} are mutually
independent. Throughout the study, the notation
X^tjt0 means the estimated value of random variable
X at time t with information up to time t
0
.
3.3. Objective Function
The novel objective function (performance criterion)
we analyze is given by
J ¼ E
XN
t¼1
at  at1ð Þ0At at  at1ð Þ þ bt0Btbt þ ltðhtÞ
 (
þ aNþ1  aNð Þ0ANþ1 aNþ1  aNð Þ

;
ð3Þ
in which At is the unit cost matrix of further worsen-
ing the disease, Bt is the unit cost of administering
disease control (i.e., further adjusting the modifiable
disease risk factor), and the scalar ltðhtÞ is the cost of
taking tests/measurements in period t, which
depends on the test control variable, ht. The objective
function consists of four terms: (i) (at  at1)0At(at 
at1) is the cost of relative change in the system state
random variable (i.e., disease progression) between
the previous period t  1 and the current period t
(whereas the traditional LQG objective minimizes
at
0
Atat as explained in subsection 1.2), (ii) bt
0Btbt is the
cost of controlling the disease risk factors including
side effects and complications of medical or surgical
treatments, (iii) ltðhtÞ is the cost of taking tests, and
(iv) (aN+1  aN)0AN + 1(aN + 1  aN) is the terminal
cost of relative state change at the end of the treat-
ment horizon. The quadratic form of the first part of
the objective function ensures that a large disease
worsening is penalized more aggressively than a
small one. Furthermore, achieving a large adjustment
in disease risk factors may require more aggressive
treatments (e.g., surgery or laser therapy), which are
associated with higher monetary costs as well as more
side effects and discomfort than a smaller change in
risk factors, which can often be achieved by simpler
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treatments such as medications. Hence, the cost associ-
ated with a big relative change in a patient’s disease
risk factors is much higher than a small one, so the
quadratic form of the second part of the objective
function is a good choice for our application.
One might try to define the first part of the objective
function as minimizing the deviation of the current
state from the patient’s baseline state (i.e., minimizing
E
P
t
½ðat  a0Þ0Atðat  a0Þ þ bt0Btbt þ ltðhtÞ). Note
that this is not an appropriate objective for irre-
versible diseases because, according to our experi-
ments, the model will attempt to reverse the disease
progression and send the state back to its baseline
(which we know is biologically impossible) by mak-
ing extreme and often infeasible changes to state vari-
ables that are not valid clinically. Moreover, such an
objective function assigns quadratically increasing
cost to additional disease progression measured as
the current deviation from its baseline, which can
easily overshadow the other cost elements in the
objective function (i.e., treatment and monitoring
costs). This will result in recommending the most
aggressive treatment and monitoring regimes for all
patients when the cost associated with deviation of
current state from its baseline overshadows the other
two costs in the objective function regardless of how
bad the current state is. We believe that good clinical
practice is always careful to note the latest disease
state, with any worsening being of concern. Our
objective function achieves this without introducing
the problems noted above.
Another alternative approach is to define the
state as ~at ¼

at
at1

, and minimize E
P
t
½~at0 ~At~at þ
bt
0Btbt þ ltðhtÞ. While it is possible to develop an
alternative formulation equivalent to the one we pre-
sented above based on this new definition of state, ~At
in the objective function of the alternative formulation
is a singular (non-invertible) cost matrix (more specif-
ically, ~At ¼

At At
At At

; calculation not shown).
However, we would need to invert this matrix to find
a closed-form solution for optimal disease control.
Hence, the alternative formulation makes it harder to
derive a closed-form solution for the optimal disease
control. Note that, in the formulation proposed in our
study, At is always invertible because A is a cost
matrix and, by definition, it is diagonal with only
non-negative terms on the diagonal.
3.4. Kalman Filter and Kalman Smoother
When the state transition and measurement processes
are both in the form of first-order difference equations
with Gaussian white noises, the optimal state estima-
tion method that minimizes the mean squared error
of the estimate is given by the Kalman filter (Kalman
1960). The Kalman filter obtains the prediction of state
mean and covariance at time t with information up to
time t  1, a^tjt1 and R^tjt1 respectively, and the cur-
rent reading, zt, as inputs to the algorithm and calcu-
lates the filtered state (i.e., optimal estimate of the true
state) mean and covariance, a^tjt and R^tjt respectively.
The optimal state mean estimate at time t with
information up to time t, a^tjt, is given by
a^tjt ¼ a^tjt1 þ Kt~yt; ð4Þ
where a^tjt1 is the predicted state mean at time t
given information up to time t  1 and ~yt is the
measurement residual (error) given by
a^tjt1 ¼ Tt1a^t1jt1 þ Gt1bt1; ð5Þ
~yt ¼ zt  Zta^tjt1; ð6Þ
and Kt is the Kalman gain given by
Kt ¼ R^tjt1Zt0S1t ; ð7Þ
in which St is the predicted covariance around the
measurement given by ZtR^tjt1Zt0 þHðhtÞt . The pre-
dicted state covariance at time t given the informa-
tion up to time t  1, R^tjt1, and the most recent
state covariance estimate at time t with information
up to time t, R^tjt, satisfy
R^tjt ¼ R^tjt1  R^tjt1Zt0 ZtR^tjt1Zt0 þHðhtÞt
 1
ZtR^tjt1 ¼ I  KtZtð ÞR^tjt1;
ð8Þ
R^tjt1 ¼ Tt1R^t1jt1Tt10 þQt1: ð9Þ
The initial state mean and covariance, a^1j0 and R^1j0
respectively, are calculated based on population
data from clinical trials. So, ~y1 ¼ z1  Z1a^1j0 and
S1 ¼ Z1R^1j0Z10 þ Hðh1Þ1 . For more discussion on Kal-
man filter, see Bertsekas (1995) and Harvey (1990).
Because of the special form of the objective function
that minimizes relative state change from time t  1
to time t (i.e., disease progression), we need to refine
the estimation of previous state mean and covariance
(a^t1jt and R^t1jt, respectively) after a new measure-
ment is taken at time t. This is called state smoothing
and can be done via a fixed-interval Kalman smoother
as follows.
a^t1jt ¼ a^t1jt1 þ R^t1 a^tjt  a^tjt1
	 

; ð10Þ
R^t1jt ¼ R^t1jt1 þ R^t1 R^tjt  R^tjt1
	 

R^t1
0; ð11Þ
in which R^t1 ¼ R^t1jt1Tt10R^1tjt1. A derivation of
the fixed-interval Kalman smoothing can be found
in Ansley and Kohn (1982).
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The control system block diagram is depicted in
Figure 1. The dashed arrows indicate that the infor-
mation is carried over from the current period, t, to
the next period, t + 1. The values in parentheses are
not observable. Suppose the patient is in disease
state at when visiting the doctor’s office. Based on
the optimal test control action ht (already deter-
mined in the previous time period), all or a subset of
tests are performed on the patient. The noisy obser-
vation/reading, zt, is then sent to the Kalman Filter.
Based on the predicted and observed states, the Kal-
man Filter algorithm calculates the best estimate of
the mean and covariance of the patient’s disease
state in period t, a^tjt and R^tjt respectively, and sends
the filtered values to both the Kalman Smoother and
the controller (i.e., the decision support system itself
for this analysis). The Kalman Smoother will then
modify the best estimates of the state mean and
covariance in period t  1, a^t1jt and R^t1jt respec-
tively, and send the smoothed values to the con-
troller. Notice that this is a key departure from the
traditional methodology. The controller receives both
the filtered and smoothed values of the patient’s dis-
ease state mean and covariance (the information
state for the optimization component of the model)
and outputs the optimal treatment and test control
actions, bt and h

tþ1. Finally, the prediction of the
state mean and covariance in period t + 1, a^tþ1jt and
R^tþ1jt, is sent to the Kalman filter and smoother to be
used in the following time period.
In section 4, we focus on the controller (decision
support tool) and show how the optimal disease and
test control actions (bt and h

tþ1, respectively) can be
calculated given the information state }t ¼
ða^tjt; R^tjt; a^t1jt; R^t1jtÞ. For convenience, Table 1 pro-
vides a list of important notations we used in our
modeling.
3.5. Separation of Estimation and Control
One-way separation of estimation and control: A control
law is a function selected by the controller from the
set of all admissible functions based on all observa-
tions available at the time of the decision. This func-
tion generates a control action to be applied to the
system. The problem is to make an optimal selection
of such functions for all time steps that achieves the
minimum expected cost (defined by the objective
function) for the control horizon of the problem. For
the general stochastic control problem with imperfect
observations, given all the observations and previous
control actions, state estimation from a noisy mea-
surement is always independent of the control law.
This is because the conditional density of the state
given all the observations and the control actions is
independent of the control law. This result is called
the separation principle in control theory (see Witsen-
hausen 1971). The only underlying assumption for the
separation principle to hold is to have one controller
(i.e., centralized information) with perfect recall (i.e.,
the information on the previous observations and
control actions do not get forgotten).
In general, the control law depends on the estimate
of the system state; however, the estimate at time t is
independent of all control laws given all observations
up to time t and all the control actions up to time
t  1. This is also known as the one-way separation
Figure 1 Control System Block Diagram
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of estimation and control. Since our LQG model is a
special case of the general stochastic control problem
with centralized information and perfect recall, the
one-way separation principle holds. As seen in sec-
tion 3.4, the optimal state estimation at time t,
described by a^tjt and R^tjt, is given by the Kalman fil-
ter (Equations 4–9) and is independent of the control
law given all the previous observations and control
actions.
Two-way separation of estimation and control: For
LQG stochastic systems in which (i) the transition
and measurement equations are linear in state and
control action, (ii) the objective function penalizes
the quadratic cost of current state, and (iii) the
state and measurement noises are Gaussian, it has
been shown that the control law is also indepen-
dent of the state estimation (Meier et al. 1967).
Therefore, for this traditional form of LQG models,
we have two-way separation of the estimation and
the control; namely, the estimation is independent
of the control law and the control law is indepen-
dent of the estimation. In section 4, we show for
the new objective of minimizing the relative change
in state, which involves two correlated state vari-
ables of current and previous time periods and
requires smoothing in addition to filtering and
prediction, that the optimal control law is still
independent of the state estimate. Thus, in this
new and more complex environment, the two-way
separation still holds. Furthermore, the optimal
control action is linear in the state estimate. This
is extremely desirable for application because the
control law is data independent and can be calcu-
lated offline (which greatly reduces the computa-
tional burden). The two-way separation of
estimation and control for this special case of
LQG models is a fundamental finding, which is
critical to solution tractability.
Table 1 List of Important Model Notation
Notation General type [size in case study] Description
at Vector [9 9 1] Disease state at time t
Tt Square matrix [9 9 9] State transition matrix governing the underlying disease progression dynamics at time t
bt Vector [1 9 1]* Disease control action—how much to reduce IOP at time t
Gt Square matrix [9 9 1]* Coefficient capturing the effect of disease control action at time t on the next period state
gt Vector [9 9 1] Disease process noise at time t
Qt Square matrix [9 9 9] Covariance of the disease process noise at time t
zt Vector [9 9 1] Observation/measurement vector at time t
Zt Square matrix [9 9 9] Observation/measurement matrix that determines how components of the true state are
observed at time t
ɛt Vector [9 9 1] Measurement process noise at time t
ht Discrete choices [3 choices] Test/measurement control action—which subset of tests to take at time t,e.g., no test, only
IOP test, or both IOP and VF tests
H
ðht Þ
t Square matrix [9 9 9] Covariance of the measurement process noise at time t that depends on which tests are
taken at timet
a0 Vector [9 9 1] Initial state
a^0or a^1j0 Vector [9 9 1] Estimate of the initial state mean
R^0or R^1j0 Square matrix [9 9 9] Estimate of the initial state covariance
a^t jt 0 Vector [9 9 1] Estimate of state mean at time t with information up to time t
0
**
R^t jt 0 Square matrix [9 9 9] Estimate of state covariance at time twith information up to time t
0
**
At Square matrix [9 9 9] Cost of further worsening of the disease at time t—e.g., cost of vision loss due to glaucoma
Bt Square matrix [1 9 1]* Cost of further adjusting the modifiable disease risk factor at time t—e.g., cost of further
lowering the IOP
lt ðht Þ Set of scalars [3 scalars] Cost of taking tests/measurements at time t that depends on which tests are taken at timet
J Scalar Expected total cost during the entire control horizon
Kt Square matrix [9 9 9] Kalman gain at time t
~y t Vector [9 9 1] Measurement residual at time t—the difference between observed and predicted
measurement at time t
St Square matrix [9 9 9] Predicted covariance around the measurement at time t
R^t Square matrix [9 9 9] Smoothing adjustment factor at time t
℘t Collection of two vectors [9 9 1] and two
matrices [9 9 9]
Information state at time t, which includes filtered and smoothed disease state mean and
covariance
Vt(℘t) Scalar Value function at time t—the minimum expected cost from period t to N, the end of the
control horizon, given the information state ℘t
Ut Square matrix [9 9 9] Control law at time t, given by Equation (31)
Notes: Auxiliary notation used in section 4 to prove Theorems 1–3 are not shown in this table; they are defined upon introduction in section 4. *Note that
since glaucoma has only one controllable risk factor (i.e., IOP), in our case study of glaucoma, bt and Bt become scalars and Gt becomes a vector.
**Smoothing, filtering, and prediction refer to the case in which t
0
> t, t
0
= t, and t
0
< t, respectively.
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4. Derivation of Optimal Disease and
Test Controls
In this section, we derive the optimal disease and test
control actions given the information state at time t,
℘t, which is defined as the filtered state mean and
covariance at time t and the smoothed state mean and
covariance at time t  1 with information up to time
t, that is, }t ¼ ða^tjt; R^tjt; a^t1jt; R^t1jtÞ.
In terms of ℘t, a dynamic programming algorithm
can be derived to find the optimum disease and test
controls. The value function, Vt(℘t), can be found
recursively as follows.
Vt }tð Þ ¼ min
bt;htþ1
Ltð}t; bt; htþ1Þ þ E
ztþ1
Vtþ1 }tþ1ð Þ½ 
 
;
t ¼ 1; . . .;N  1;
ð12Þ
where Vt(℘t) is the minimum expected cost from
period t to N, the end of the control horizon, given
the information state ℘t, and Ltð}t; bt; htþ1Þ. Here
Ltð}t; bt; htþ1Þ is the expected instantaneous (one-
stage) cost incurred in period t given that the infor-
mation state is ℘t and the control actions bt and htþ1
are chosen, and it is computed as
Ltð}t; bt; htþ1Þ ¼ E at  at1ð Þ0At at  at1ð Þj}t
 
þ b0tBtbt þ ltþ1ðhtþ1Þ:
ð13Þ
The boundary condition is given by
VN }Nð Þ ¼ min
bN
~LNð}N; bNÞ
 
; ð14Þ
where ~LNð}N; bNÞ is the expected cost incurred in
the final period N if the information state is ℘N and
the disease control action bN is chosen. The mini-
mum cost during the entire control horizon can,
therefore, be obtained by
J ¼ l1ðh1Þ þ V1ð}1Þ; ð15Þ
in which l1ðh1Þ is the cost of initial tests during the
patient’s first office visit and V1(℘1) is the minimum
cost to go from period 1 to the end of control hori-
zon obtained recursively via Equations 12 and 14.
We assume all diagnostic tests are taken during the
first visit, so a baseline of all readings is established.
In the remainder of this section we use an induction
argument to prove the following theorems.
THEOREM 1. For arbitrary time t (t = 1, . . ., N), the
control law is independent of the state estimate (i.e., we
have two-way separation of optimal estimation and
control). Moreover, the optimal disease control, bt , is
linear in the filtered state mean, a^tjt.
THEOREM 2. At an arbitrary time t (t = 1, . . ., N), the
optimal monitoring schedule, htþ1; h

tþ2; . . ., can be found
by solving a continuous-state discrete-action MDP model
with filtered and smoothed covariance matrices of the
state serving as the information state and the Kalman
filter and smoother equations acting as the system
dynamics.
THEOREM 3. For arbitrary time t (t = 1, . . ., N), the
value function with information up to time t has the
following form.
Vt }tð Þ ¼ a^tjt  a^t1jt
	 
0
At a^tjt  a^t1jt
	 

þ tr AtR^tjt
 þ a^tjt0Pta^tjt þ tr PtR^tjt 
þ Vht }ht
	 
þ bt;
ð16Þ
in which Vht ð}ht Þ represents the recursive terms that only
depend on measurement control actions, that is, when to
take tests and which test(s) to take. They do not depend on
observations or on disease control actions. Therefore, the
measurement control problem can be solved separately from
the treatment control problem. }ht represents those elements
of information state that are only affected by measurement
control actions (i.e., }ht ¼
	
R^tjt; R^t1jt


), and bt is a con-
stant. Vht ð}ht Þ and bt will be obtained later in the proof.
PROOF BY INDUCTION. In Appendix A we prove that
the value function in the final period is given by
VN }Nð Þ¼ a^NjN a^N1jN
	 
0
AN a^NjN a^N1jN
	 

þ tr ANR^NjN
 þ a^NjN 0PN a^NjNþ tr PNR^NjN 
þ tr AN R^N1jNTN1R^N1jN R^N1jNTN10
	 
 
þ tr ~PNþ1R^NjN
 þ tr ANþ1QN½ ;
ð17Þ
where tr represents the trace of the matrix. By com-
paring Equations 16 and 17, we obtain our basis for
induction:
VhN }
h
N
	 
 ¼ tr AN R^N1jN  TN1R^N1jN	
R^N1jNTN10

þ tr ~PNþ1R^NjN ; ð18Þ
bN ¼ tr ANþ1QN½ : ð19Þ
Assume the induction hypothesis that
Vtþ1 }tþ1ð Þ ¼ a^tþ1jtþ1  a^tjtþ1
	 
0
Atþ1 a^tþ1jtþ1  a^tjtþ1
	 

þ tr Atþ1R^tþ1jtþ1
 þ a^tþ1jtþ10Ptþ1a^tþ1jtþ1
þ tr Ptþ1R^tþ1jtþ1
 þ Vhtþ1 }htþ1	 
þ btþ1:
ð20Þ
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We show that Vt(℘t) follows the form given in
Equation 16 to complete the induction step. From
Equation 12 we know the general form of value
function is
Vt }tð Þ ¼ min
bt;htþ1
Ltð}t; bt; htþ1Þ þ E
ztþ1
Vtþ1 }tþ1ð Þ½ 
 
;
ð21Þ
in which the information state at time t + 1, ℘t+1, is
a function of ℘t, bt, htþ1, and ztþ1. The expected
instantaneous cost in period t, Ltð}t; bt; htþ1Þ, is
given in Equation 13. Application of Lemma 3 to the
expectation in Equation 13 results in
Ltð}t; bt; htþ1Þ ¼ a^tjt  a^t1jt
	 
0
At a^tjt  a^t1jt
	 

þ tr At R^tjt þ R^t1jt
	
Tt1R^t1jt  R^t1jtTt10


þ b0tBtbt þ ltþ1ðhtþ1Þ:
ð22Þ
Replacing Ltð}t; bt; htþ1Þ and Vt+1(℘t+1) in Equation
21 by the values given by Equations 22 and 20
respectively, yields
Vt }tð Þ ¼ min
bt;htþ1
a^tjt  a^t1jt
	 
0
At a^tjt  a^t1jt
	 
n
þtr At R^tjt þ R^t1jt  Tt1R^t1jt
	
R^t1jtTt10

þ b0tBtbt þ ltþ1ðhtþ1Þ
þ E
ztþ1
a^tþ1jtþ1  a^tjtþ1
	 
0
Atþ1 a^tþ1jtþ1  a^tjtþ1
	 
h
þa^tþ1jtþ10Ptþ1a^tþ1jtþ1
þ tr Atþ1R^tþ1jtþ1 
þtr Ptþ1R^tþ1jtþ1
 þ Vhtþ1 }htþ1	 
þ btþ1;
ð23Þ
Replacing E
ztþ1
½ða^tþ1jtþ1  a^tjtþ1Þ0Atþ1ða^tþ1jtþ1  a^tjtþ1Þ
and E
ztþ1
½a^tþ1jtþ10Ptþ1a^tþ1jtþ1 using Lemmas 7 and 8 in
Appendix B, respectively, yields
Vt }tð Þ ¼ min
bt;htþ1
a^tjt  a^t1jt
	 
0
At a^tjt  a^t1jt
	 
n
þtr At R^tjt þ R^t1jt  Tt1R^t1jt
	
R^t1jtTt10

þ b0tBtbt þ ltþ1ðhtþ1Þ
þ ðTt  IÞa^tjt þ Gtbt
	 
0
Atþ1 ðTt  IÞa^tjt þ Gtbt
	 

þtr Atþ1 TtR^tjtTt0 þQt  R^tþ1jtþ1
	
R^tþ1jtþ1R^t 0  R^t R^tþ1jtþ1 þ R^tjtþ1


þðTta^tjt þ GtbtÞ0Ptþ1ðTta^tjt þ GtbtÞ
þtr Ptþ1 TtR^tjtTt0 þQt  R^tþ1jtþ1
	 
 
þtr Atþ1R^tþ1jtþ1
 þ tr Ptþ1R^tþ1jtþ1 
þVhtþ1 }htþ1
	 
þ btþ1:
ð24Þ
Canceling terms results in
Vt }tð Þ¼min
bt;htþ1
a^tjta^t1jt
	 
0
At a^tjta^t1jt
	 
n
þtr At R^tjtþR^t1jtTt1R^t1jt
	
R^t1jtTt10

þb0tBtbtþltþ1ðhtþ1Þ
þ ðTtIÞa^tjtþGtbt
	 
0
Atþ1 ðTtIÞa^tjtþGtbt
	 

þðTta^tjtþGtbtÞ0Ptþ1ðTta^tjtþGtbtÞ
þtr Atþ1þPtþ1ð Þ TtR^tjtTt0
	 
 þtr Atþ1þPtþ1ð ÞQt½ 
þtr Atþ1 R^tjtþ1R^t R^tþ1jtþ1R^tþ1jtþ1R^t 0
	 
 
þVhtþ1 }htþ1
	 
þbtþ1:
ð25Þ
The terms in Equation 25 can be separated into three
types: (i) those terms whose values are known at time
t with information up to time t, (ii) those that depend
only on disease control action, bt, and (iii) those that
depend only on test control action, htþ1. Hence, the
minimization over bt and htþ1 can be separated as
Vtð}tÞ ¼ Vð1Þt ð}tÞ þ Vð2Þt ð}tÞ þVð3Þt ð}tÞ in which
V
ð1Þ
t }tð Þ¼ a^tjt a^t1jt
	 
0
At a^tjt a^t1jt
	 

þ tr At R^tjtþ R^t1jtTt1R^t1jt R^t1jtTt10
	 
 
þ a^0tjt ðTt IÞ0Atþ1ðTt IÞþTt0Ptþ1Tt
	 

a^tjt;
ð26Þ
V
ð2Þ
t }tð Þ ¼ min
bt
bt
0 Bt þ Gt0ðAtþ1 þ Ptþ1ÞGtð Þbtf
þ a^tjtððTt  IÞ0Atþ1 þ Tt0Ptþ1ÞGt
	 

bt
þbt0 Gt0ðAtþ1ðTt  IÞ þ Ptþ1TtÞa^tjt
	 

;
ð27Þ
V
ð3Þ
t }tð Þ¼ tr Atþ1þPtþ1ð Þ TtR^tjtTt0
	 
 
þ tr Atþ1þPtþ1ð ÞQt½ þbtþ1
þmin
htþ1
ltþ1ðhtþ1Þþ tr Atþ1 R^tjtþ1 R^t R^tþ1jtþ1
	
R^tþ1jtþ1R^t 0

þVhtþ1 }htþ1	 
:
ð28Þ
As before, the minimization over bt is denoted by ~Jt,
so
~Jt ¼ min
bt
fb0t Bt þ Gt0ðAtþ1 þ Ptþ1ÞGtð Þbt
þ a^0tjt ðTt  IÞ0Atþ1 þ Tt0Ptþ1
	 

Gt
	 

bt
þ bt0 Gt0 Atþ1ðTt  IÞ þ Ptþ1Ttð Þa^tjt
	 
g
ð29Þ
The minimization over bt can be performed by com-
pletion of squares (similar to what is done in
Lemma 5 for the minimization over bN) to yield
Equations 30–33. The optimal disease control at time
t is given by
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bt ¼ Uta^tjt; ð30Þ
in which the control law, Ut, is given by
Ut ¼
	
Bt þ Gt0ðAtþ1 þ Ptþ1ÞGt

1	
Gt
0Atþ1ðTt  IÞ þ Gt0Ptþ1Tt


:
ð31Þ
Moreover, the result of minimization over bt is
given by
~Jt ¼ a^0tjt~Ptþ1a^tjt; ð32Þ
in which
~Ptþ1 ¼ ðTt  IÞ0Atþ1Gt þ Tt0Ptþ1Gt
	 

Bt þ Gt0ðAtþ1 þ Ptþ1ÞGtð Þ1
Gt
0Ptþ1Tt þ Gt0Atþ1ðTt  IÞð Þ:
ð33Þ
As seen in Equation 30, the optimal disease control
bt is a linear function of the filtered state mean a^tjt.
It is worth noting that this function (more precisely,
the control law Ut) depends only on parameters of
the system dynamics and the objective function cost
inputs. Hence, the control law is data independent
and can be calculated offline prior to solving the
measurement and control problems. As seen in
Equations 4–11, the optimal state estimation is inde-
pendent of the control law. We also just showed
that the optimal control law is independent of
the state estimation. This completes proof of
Theorem 1. h
Replacing the minimization over bt in Equation 27
by its value given by Equation 32 results in
Vt }tð Þ¼ a^tjt a^t1jt
	 
0
At a^tjt a^t1jt
	 

þ tr At R^tjtþ R^t1jtTt1R^t1jt R^t1jtTt10
	 
 
þ a^0tjt ðTt IÞ0Atþ1ðTt IÞþTt0Ptþ1Tt ~Ptþ1
	 

a^tjt
þ tr Atþ1þPtþ1ð Þ TtR^tjtTt0
	 
 
þmin
htþ1
ltþ1ðhtþ1Þþ tr Atþ1 R^tjtþ1 R^t R^tþ1jtþ1
	
R^tþ1jtþ1R^t 0

þVhtþ1 }htþ1	 

þ tr Atþ1þPtþ1ð ÞQt½ þbtþ1:
ð34Þ
Letting
Pt ¼ ðTt  IÞ0Atþ1ðTt  IÞ þ Tt0Ptþ1Tt  ~Ptþ1; ð35Þ
and replacing tr½ðAtþ 1 þ Ptþ1ÞðTtR^tjtTt0Þ in Equation
34 by its other form given by Lemma 9, Equation 34
can be written as follows to match the form of value
function we claimed in Equation 16.
Vt }tð Þ ¼ a^tjt  a^t1jt
	 
0
At a^tjt  a^t1jt
	 

þ tr AtR^tjt
 þ a^tjt0Pta^tjt þ tr PtR^tjt 
þ tr At R^t1jt  Tt1R^t1jt  R^t1jtTt10
	 
 
þ tr ~Ptþ1 þ Atþ1Tt þ Tt0Atþ1  I
	 

R^tjt
 
þmin
htþ1
ltþ1ðhtþ1Þ þ tr Atþ1 R^tjtþ1  R^t R^tþ1jtþ1
	
R^tþ1jtþ1R^t 0

þ Vhtþ1 }htþ1	 

þ tr Atþ1 þ Ptþ1ð ÞQt½  þ btþ1:
ð36Þ
Now, by comparing Equations 36 and 16, it can be
easily seen that for t = 1, . . ., N  1
Vht }
h
t
	 
 ¼ tr At R^t1jt  Tt1R^t1jt  R^t1jtTt10	 
 
þ tr ~Ptþ1 þ Atþ1Tt þ Tt0Atþ1  I
	 

R^tjt
 
þmin
htþ1
ltþ1ðhtþ1Þ þ tr Atþ1 R^tjtþ1  R^t R^tþ1jtþ1
	
R^tþ1jtþ1R^t 0

þ Vhtþ1 }htþ1	 
;
ð37Þ
and
bt ¼ tr Atþ1 þ Ptþ1ð ÞQt½  þ btþ1; ð38Þ
while from Equations 18 and 19 we know for t = N
VhN }
h
N
	 
 ¼ tr AN R^N1jN  TN1R^N1jN	
R^N1jNTN10

þ tr ~PNþ1R^NjN ; ð39Þ
and
bN ¼ tr ANþ1QN½ : ð40Þ
Hence, the proof of Theorem 3 (i.e., the value func-
tion we claimed in Equation 16) is complete.
Note that the dynamic program defined by value
function Vht ð}ht Þ for t = 1, . . ., N can be solved to find
the optimal monitoring schedule. We succinctly high-
light the elements of this dynamic program. The infor-
mation state of the model (which can be thought as
summarizing the sufficient statistics) is }ht ¼
ðR^tjt; R^t1jtÞ. The action space is h 2 Θ, where Θ is the
set of all available tests for the corresponding disease.
Equations 8, 9, and 11 state the system dynamics of
the model, while Equation 37 specifies the optimality
equation (or Bellman equation). The boundary condi-
tions are given in Equation 39. This completes the
proof of Theorem 2.
5. Case Study of Glaucoma
Thus far we have presented the modeling framework
in its general form and derived the optimal disease
and test control actions. In this section, we provide a
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proof of concept by applying our approach to glau-
coma and demonstrating how it can help guide clini-
cians in tailoring disease monitoring and treatment
control.
Glaucoma is a major public health problem affect-
ing almost 3 million patients in the United States
(Vajaranant et al. 2012) and over 60 million patients
worldwide (Tham et al. 2014). Glaucoma is the sec-
ond leading cause of blindness in the US and a lead-
ing cause of visual impairment among Americans
(Stein et al. 2011). In this section, we show how the
modeling framework and solution approaches
described in sections 3 and 4 can be applied to help
clinicians in caring for patients with glaucoma. Fur-
thermore, we elaborate on additional features of our
approach designed specifically for glaucoma. Numer-
ical results presented in this section are based on data
from patients with glaucoma who were enrolled in
two large clinical trials.
5.1. Glaucoma
Glaucoma is a progressive eye disease which can
cause irreversible vision loss and blindness if not ade-
quately monitored and treated. From a societal per-
spective, the direct medical costs of managing
glaucoma are estimated to total over 2.86 billion USD
annually (Rein et al. 2006). Furthermore, on a per
patient basis, costs more than quadruple when
patients progress from early to advanced glaucoma
(Lee et al. 2006). Key risk factors associated with glau-
coma development and its progression include: non-
white race, older age, elevated intraocular pressure
(IOP), genetics, and family history (Tielsch et al.
1990). It is worth noting that the patient’s IOP (i.e., the
pressure inside the eye) is the only known control-
lable/modifiable glaucoma risk factor. Therefore, the
current management of glaucoma focuses on lower-
ing the eye pressure by establishing a “target IOP,”
which is the level of IOP that the clinician feels is low
enough to slow disease progression sufficiently (Jam-
pel 1997).
Patients with glaucoma are monitored for disease
progression using several quantitative tests. Two pri-
mary methods to monitor a patient are: (i) tonometry
(or measuring the IOP), and (ii) perimetry (or visual
field (VF) testing). Tonometry measures the patient’s
IOP, is relatively easy to perform, and is part of a stan-
dard eye examination. In most patients, vision loss
from glaucoma occurs because elevated IOP damages
the optic nerve, the structure that carries visual infor-
mation to the brain for interpretation and processing
(Sommer et al. 1991). Vision loss caused by glaucoma
cannot be reversed but treatment can help slow or
halt future vision loss (Weinreb and Khaw 2004).
Lowering IOP has been shown to reduce the risk of
disease progression and is the primary treatment goal
in glaucoma management (Hyman et al. 2010, Leske
et al. 2003, Maier et al. 2005). With glaucoma, patients
often progressively lose peripheral vision and eventu-
ally as the disease worsens, central vision. The VF test
quantifiably measures the extent and rate of periph-
eral vision loss by examining the sensitivity of the eye
to light stimuli of varying intensities. It is more time-
consuming than checking IOP but provides important
information on the status of the disease. VF testing
can be anxiety-inducing and challenging for patients
as it requires patient attention and cooperation. Two
key global performance measures from VF testing
include Mean Deviation (MD) and Pattern Standard
Deviation (PSD), which estimate the extent deviation
of peripheral vision from a reference population who
do not have glaucoma (Choplin and Edwards 1995).
MD is usually a negative number; higher values of
MD (i.e., values closer to zero) correspond to better
vision quality (less vision loss). PSD is usually a posi-
tive number. MD, PSD, and IOP are all measured on a
continuous scale.
It is well established from prior work that both IOP
and VF tests can be associated with noise. For exam-
ple, patient MD and PSD performance on an auto-
mated VF test can fluctuate considerably from one
test to the next (Choplin and Edwards 1995). Like-
wise, IOP can fluctuate from hour to hour and day to
day (Wilensky et al. 1993). To take such noise into
consideration in deciding how to monitor the patient
optimally and determine an appropriate target IOP,
we harness the Kalman filter method (Kalman 1960)
to remove noise from the raw measurements and pro-
vide a dynamic model for the state over time.
There are a number of treatments available to lower
the IOP for a patient with glaucoma. Different eye
drops, laser therapies, and incisional surgery can
reduce the IOP to any number above 6 mmHg. How-
ever, glaucoma medications can be expensive and can
have serious side effects including stinging, blurred
vision, eye redness, itching, burning, low blood pres-
sure, reduced pulse rate, fatigue, shortness of breath,
headache, and depression. Therefore, the goal is to
find the optimal target IOP for each patient, which
corresponds to an IOP that is low enough to suffi-
ciently slow disease progression but not overly low so
as to subject the patient to unnecessary treatments.
The appropriate target IOP varies from one patient to
another as some patients (eyes) experience progres-
sion at a certain IOP level while others do not.
In current practice it is common to use fixed-inter-
val monitoring regimes to test for disease progression.
Furthermore, for each patient (eye), the eye care pro-
fessional must regularly make a gestalt-based esti-
mate of a reasonable target IOP that considers the
patient’s individual risk of disease progression and
the side effects and costs associated with lowering the
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IOP. Prior studies in glaucoma management have
employed various machine learning algorithms to
predict progression of glaucoma progression (Bowd
et al. 2012, Goldbaum et al. 2012, Sharpsten et al.
2014, Yousefi et al. 2014, Yousefi et al. 2016). Simula-
tion models of glaucoma progression have been
developed to evaluate the cost-effectiveness of fre-
quent testing in patients with glaucoma (Boodhna
and Crabb 2016) as well as to evaluate different treat-
ment strategies (Van Gestel et al. 2010). However, to
the best of our knowledge, no optimization-based
approach presently exists to jointly determine how
best to monitor a patient with glaucoma and how best
to control the disease. Our approach considers the his-
tory of the patient (prior test performances) and her
unique disease dynamics to provide clinicians with (i)
a personalized monitoring regime to achieve an accu-
rate assessment of whether there is disease progres-
sion (exploration), and (ii) in a menu format, how the
glaucoma is likely to progress for different target IOP
levels; the doctor can leverage these to devise an indi-
vidualized treatment plan for the particular patient
(exploitation). As a feature of our model, the clinician
is able to select the desired aggressiveness level to
monitor and treat the patient based on the unique
characteristics/circumstances of the specific patient.
We will elaborate on this menu of options in subsec-
tion 5.5.
Figure 2 depicts a high-level overview of our
dynamic monitoring and control decision support
framework for patients with glaucoma. It serves as a
schematic table of contents for what follows in the
remainder of this section. It shows how different parts
of the modeling framework are linked together and
provides the corresponding subsection/equations for
each part. At each office visit, IOP and/or VF test(s)
are performed. The raw measurements from these
tests (which are known to be noisy) are fed into a
Kalman filter to obtain an optimal estimation of the
current disease state for a particular eye. Then, the
estimate of the previous state is refined via a Kalman
smoother given the new information acquired during
the visit. Each patient’s label/type (fast-, slow-, or
non-progressor) determines the estimate of how
quickly the patient’s glaucoma is likely to progress in
the future. The decision support tool provides an opti-
mal monitoring schedule (i.e., the timing of the next
exam/test and which tests the patient should take)
and a personalized target IOP for the patient for dif-
ferent aggressiveness levels/options (super-high,
high, moderate, low, or super-low). Finally, the clini-
cian chooses an aggressiveness option from the menu
of choices that is appropriate for the individual
patient.
5.2. Patient Disease State
We use a nine-dimensional state vector, at, to model
the patient’s disease state. The elements of the state
vector include MD, PSD, and IOP together with their
discrete time first and second derivatives (i.e., velocity
and acceleration, respectively);
at ¼
½MD MD0 MD00 PSD PSD0 PSD00
IOP IOP0 IOP000:
ð41Þ
The nonlinear behavior of disease dynamics is cap-
tured by including the velocity and acceleration of
key disease state elements in the state vector. This is
known to be an effective way to linearize a non-
linear model of state evolution (see Bertsekas 1995).
MD, PSD
0
, and IOP
0
are the slope of a linear regres-
sion of the latest three MD, PSD, and IOP measure-
ments, respectively. MD
0 0
, PSD
0 0
, and IOP
0 0
are the
difference of the latest two MD
0
, PSD
0
, and IOP
0
val-
ues divided by the time interval between them. It is
Figure 2 Illustration of the Decision Support Framework Showing the Model Inputs and Outputs As Well As the Sequence of Main Steps of the Dis-
ease Monitoring and Control Algorithm [Color figure can be viewed at wileyonlinelibrary.com]
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worth noting that, in the application of our model-
ing framework to glaucoma, the disease control
action (i.e., bt in Equation 1), is defined as the
amount in mmHg to reduce the patient’s IOP at time
t. This value is determined by the optimization
model, not by the user/clinician.
5.3. Data
To parameterize and validate our model, we use data
from two multi-center randomized clinical trials, the
Collaborative Initial Glaucoma Treatment Study
(CIGTS) (Musch et al. 1999) and the Advanced Glau-
coma Intervention Study (AGIS) (Ederer et al. 1994).
These datasets are chosen because they include struc-
tured tonometry and perimetry data (IOP and VF
readings) of glaucoma patients taken every 6 months
during the course of the trials. We match the time step
of our LQG model with these datasets to avoid the
need for data interpolation (i.e., there is a 6-month
time interval between periods t and t + 1 in our
model).
CIGTS studied newly diagnosed glaucoma patients
with mild to moderate disease who were randomized
to medical or surgical therapy and were followed for
up to 11 years with IOP and VF tests taken every
6 months to assess disease progression. In AGIS,
patients with advanced glaucoma were randomized
to laser therapy or incisional surgery and followed for
up to 11 years with IOP and VF readings taken every
6 months.
For the purpose of this case study, we excluded
patients from these trials with fewer than five read-
ings. We also restricted our focus to the patients who
received either medical or laser therapy. We excluded
glaucoma patients who received incisional surgical
interventions because incisional surgery can abruptly
change disease progression dynamics in a manner
that may be challenging to accurately model. We ran-
domly divided all eligible participants from the trials
(571 participants) into two sets of equal size: (i) a
training set, and (ii) a testing set. Both sets have
approximately the same number of mild, moderate,
and advanced glaucoma patients, with similar num-
bers of white and black patients, and equal numbers
of patients contributing data from each trial. The
training set is used for parametrization and calibra-
tion of our state space model and the testing set is
used to evaluate the performance of our approach.
5.4. Patient Types (Fast/Slow/Non-Progressor)
A fast-progressing patient is someone whose glau-
coma is worsening rapidly and is part of the subset of
patients at the greatest risk of blindness. Although
there is presently no gold standard for defining glau-
coma fast-progressors, prior literature considers a loss
of MD >1 dB per year as a reasonable identifying
feature of patients who are exhibiting fast-progression
of glaucoma (see Gardiner and Crabb 2002, Heijl et al.
2013). We built our algorithms based on this defini-
tion of fast-progressors. To classify each patient, we
calculated the slope obtained from a linear regression
of their entire set of MD readings and labeled them
as a:
• fast-progressor if the MD slope is declining by
≥1 dB/year,
• slow-progressor if the MD slope is declining
between 0 and 1 dB/year, and
• non-progressor if the MD slope is not declining.
5.5. Aggressiveness Levels/Policies/Options/
Regimes
In clinical practice, the goals of care must be tailored
to each individual patient’s needs. Rather than
proposing one solution for all patients, a more power-
ful and useful approach is to provide the clinician
with a range of options for how much effort (both
from provider and the patient) will be put into moni-
toring and how aggressively IOP should be lowered
such that future progression can be slowed. For
instance, clinicians will likely see the need to monitor
and treat a young patient who only has sight in one
eye more aggressively than an older patient with mild
glaucoma in one eye and no glaucoma in the other
eye. All else being equal, less aggressiveness may be
appropriate for a patient with multiple systemic med-
ical comorbidities who is likely to die before they go
blind from glaucoma. As a useful and not overly com-
plex approach, our clinical collaborator suggested cre-
ating optimization models tailored to three regimes,
or “options,” for monitoring and treatment to facili-
tate adoption of this system into clinical practice. We
refer to these three options as low, moderate, and high
levels of aggressiveness to represent the level of inten-
sity in care and monitoring. We also define two
extreme levels of aggressiveness: super-high and super-
low. Note that we choose these terms only for conve-
nience in presenting the five options and to make it
easier for the reader to remember the order of them in
terms of how aggressively they test and treat patients;
they are not meant to correspond to any existing
terms or approaches currently used in clinical prac-
tice. These five options are useful not only for sensi-
tivity analysis but also suggest an effective way to
implement a decision support system so that clini-
cians can pursue monitoring and treatment with the
level of intensity that they, together with the patient,
determine to be the most appropriate for each indi-
vidual. Appendix C provides insight into selecting an
appropriate aggressiveness option. It is important to
differentiate between the aggressiveness level and the
optimal control (target IOP and monitoring schedule).
Kazemian, Helm, Lavieri, Stein, and Van Oyen: Monitoring and Control of Glaucoma
Production and Operations Management 28(5), pp. 1082–1107, © 2018 Production and Operations Management Society 1095
In the treatment planning cycle, an aggressiveness
level is chosen by the clinician based on the tradeoff
between the costs of treatment (e.g., side-effects and
financial costs) and the benefits for the patient being
treated (e.g., preventing future vision loss from
glaucoma). This provides an aggressiveness regime
under which each patient’s monitoring and treat-
ment plans can be optimized individually with
respect to their particular disease trajectory and his-
tory of readings. Thus, the optimal control is per-
sonalized in terms of monitoring and treatment
decisions driven by their personal data and gov-
erned by the model for the particular aggressiveness
regime selected. Note that the regime itself does not
predetermine the monitoring and treatment plans
for the individual. For the same aggressiveness
regime, two individuals will have different histories
of test results and, therefore, potentially different
optimal decisions of when to take the next test and
which tests to take as well as different target IOPs
over time. Different aggressiveness levels translate
into different cost matrices A, B, and ltðhtÞ in our
objective function. Essentially, the more aggressive
the policy the larger the cost of disease progression
(A), which subsequently encourages the optimiza-
tion problem to suggest a larger reduction in IOP
(i.e., larger bt ) and more frequent testing. In sum-
mary, the aggressiveness level is chosen by the clini-
cian in consultation with the patient based on
treatment goals, which then sets the cost parameters
of the model, whereas the actual target IOP and
monitoring schedule are chosen by the optimization
model unique to the patient’s quantitative disease
measurements over time. The five aggressiveness
levels/options follow:
1. Super-high aggressiveness option, which drops
the IOP immediately to 6 mmHg (an ideal
level of IOP for patients with any severity of
glaucoma, but one that may be impractical
for many patients due to limitations with the
effectiveness of existing interventions, side
effects, and/or complications associated with
attaining such a low IOP),
2. High aggressiveness option, which tends to
lower the IOP by 40%–60% compared to the
patient’s treated level of IOP that was
achieved in the CIGTS/AGIS clinical trials
after the initial intervention was given,
3. Moderate aggressiveness option, which tends to
lower the IOP by 20%–40% compared to the
patient’s treated level of IOP that was
achieved in the CIGTS/AGIS clinical trials
after the initial intervention was given,
4. Low aggressiveness option, which corresponds to
the IOP achieved under no additional
interventions beyond those employed in the
CIGTS/AGIS trials, and
5. Super-low aggressiveness option, which attempts
to estimate progression of an untreated
patient with glaucoma by removing the effect
of existing interventions that were employed
in CIGTS/AGIS on the patient’s IOP.
It should be noted that the exact amount of IOP
control suggested by high, moderate, and low aggres-
siveness policies is patient-specific and is optimized
to yield the minimum total cost as defined by the
objective function. In contrast, the super-high and
super-low aggressiveness policies are static policies
that do not take the objective function into account.
They are mainly added for purposes of analysis and
comparison, but they can still provide valuable
insight in a clinical setting by presenting the clinician
the “best” and “worst” case options and their fore-
casted impact on disease progression dynamics.
These five options/levels also provide sensitivity
analysis on the model cost parameters.
5.6. System Model Parameterization
The expectation maximization (EM) algorithm was
employed to parameterize the state space model.
EM is an iterative algorithm for finding the maxi-
mum likelihood estimate of model parameters in the
presence of missing or unobserved data. The EM
algorithm alternates between the expectation step
(E-step) and the maximization step (M-step). In the
E-step, raw, noisy readings are filtered and missing
data is estimated based on the observed data and
the most recent estimate of system parameters. In
the M-step, the log-likelihood function of all data
points is maximized assuming the missing data is
given by the estimates from the E-step. For more
information about the EM algorithm, please see
Dempster et al. (1977), Digalakis et al. (1993),
Ghahramani and Hinton (1996). While the model
was presented in its general setting in section 3, for
the purpose of this case study we assume the model
parameters are time-invariant. The output of the EM
algorithm is the best estimate of system matrices
Tt = T, Qt = Q, Zt = Z, H
ðhtÞ
t ¼ HðhtÞ for t = 1, . . ., N,
and initial state mean and covariance, a^0 and R^0 (see
subsections 3.1 and 3.2 for the definition of these
parameters). We assume At = A, Bt = B, and
ltðhtÞ ¼ lðhtÞ are time-invariant. We further assume
that Gt ¼ G ¼ ½ 0 0 0 0 0 0 1 0 0 0T for
t = 1, . . ., N, because the control variable bt is
designed to control the patient’s IOP only, which is
the only controllable glaucoma risk factor. Further-
more, it is known that an intervention started or
employed at time t has instantaneous effect on low-
ering the patient’s IOP. For example, if patient’s IOP
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is 20 mmHg at time period 7 and the control
b7 ¼ 3 mmHg, the expected value of IOP right
after time period 7 is 17 mmHg. This IOP reduction
affects other state elements and progression dynam-
ics in the following time period through the transi-
tion equation. Also, note that, in our case study of
glaucoma, T, Q, Z, HðhtÞ, A, and
P^
0 are 9 9 9 matri-
ces, G and a^0 are 9 9 1 vectors, and bt, B, and lðhtÞ
are scalars. None of the square matrices are assumed
to be diagonal. This is important because, for exam-
ple, the components of T represent how each compo-
nent in the current state affects the future states. A
non-diagonal component would represent the fact
that a higher IOP will affect the change in MD in
the next period. Hence, the current disease state (in-
cluding the position, velocity, and acceleration of
key glaucoma variables) directly affects disease
progression.
We use the EM algorithm to obtain four sets of sys-
tem parameters. These sets of parameters are
obtained from (i) all patients in the training set, (ii)
only fast-progressors, (iii) only slow-progressors, and
(iv) only non-progressors, to enable stratified analy-
ses, such as in Figure 4.
The model cost parameters were estimated
based on input from our glaucoma specialist col-
laborator so that the model outputs are reasonable
from a clinical perspective. Note that it is the rela-
tive costs (rather than each absolute cost) that play
a key role in our analysis. It is beyond our scope
to obtain definitive cost parameters; however, sig-
nificant sensitivity analysis was performed around
those estimates to understand the model’s behav-
ior better and to ensure that the model, in its
entirety, provides credible decision support. In
order to construct reasonable tradeoffs between
cost parameters for each aggressiveness option in
our model, we employed a human-in-the-loop
methodology. We tested several parameter sets,
showed the resulting optimal IOP controls and
monitoring policies to our glaucoma specialist col-
laborator, and the clinician helped us fine-tune
and calibrate cost parameters. We confirmed with
our glaucoma specialist collaborator that the model
generates clinically reasonable target IOPs and
monitoring schedules for each patient under the
desired aggressiveness level. For instance, under
the high aggressiveness option, the model for fast-
progressing patients (i.e., the most aggressive com-
bination) should suggest taking both IOP and VF
tests every 6 months and a target IOP of around
6–9 mmHg. Under the low aggressiveness option,
the model for non-progressing patients (i.e., the
least aggressive combination) should suggest no
further IOP reduction and taking IOP and VF tests
every 2 years. This is in line with
recommendations put forth by the American Acad-
emy of Ophthalmology Clinical Practice Guidelines
(2015). For all other combinations of aggressiveness
level and patient severity type, the model cost
parameters were fine-tuned so it suggests a moni-
toring regime and target IOP level that are reason-
able according to expert clinical opinion and are
in between the two extreme combinations. The
behavior of optimal policies is discussed more
thoroughly in section 5.8.2.
5.7. Model Usage for a Glaucoma Patient
For a patient who is newly diagnosed with glau-
coma with no prior history of IOP and VF readings,
both tests are taken in every period (i.e., every
6 months) for the first five periods. Gardiner and
Crabb (2002) found that five initial VF test results
are a reasonable predictor of future glaucoma pro-
gression dynamics in most patients. We used five
initial VF and IOP readings to (i) obtain baseline
values for key disease state elements (i.e., MD, PSD,
and IOP), (ii) calculate the velocities and accelera-
tions of key state elements, (iii) warmup the Kalman
filter and smoother, (iv) reduce the initial uncer-
tainty surrounding a given patient’s disease state,
(v) calculate the initial 5-period rate/slope of MD
progression to label the patient as a fast-, slow-, or
non-progressor, and (vi) differentiate the patient
from the population mean and tailor the disease
transition model to the specific patient.
The system parameters obtained from all training
patients are used in the Kalman filter and the Kal-
man smoother during the warmup period. At the
end of the warmup period (i.e., after five readings),
the patient is labeled as a fast-progressor, a slow-
progressor, or a non-progressor based on her MD
progression rate. Thereafter, the Kalman filter and
smoother with type-specific system parameters (i.e.,
fast, slow, or non-progressor set of parameters) are
used. Each time a subsequent test is taken, the MD
progression slope is recalculated. We always con-
sider the latest five filtered MD values to update the
MD slope (i.e., a sliding window of length 5).
Whenever the patient’s latest MD slope indicates a
label upgrade (i.e., the patient moves from non-pro-
gressor to slow/fast-progressor, or from slow-pro-
gressor to fast-progressor), the model (i) calls for a
follow-up visit to take IOP and VF testing in the fol-
lowing time period, and (ii) labels the patient as a
suspect of the higher label/category (e.g., slow-pro-
gressor suspect or fast-progressor suspect). If the
label change is confirmed at the next follow-up visit,
the higher label is assigned to the patient. Other-
wise, the patient is returned to the previous lower
label status. Note that our analyses take a conserva-
tive approach and do not allow any label
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downgrading (on the recommendation of our glau-
coma specialist collaborator). Once the label is
upgraded for a patient, the model will recommend
applying more IOP control (i.e., greater intensity of
interventions) to slow glaucoma progression. There-
fore, it can be expected that the MD will tend to
decline less rapidly once the amount of IOP control
is increased, resulting in a lower classification/label
at some point. However, if we were to downgrade
the patient’s label and let the model decrease the
amount of IOP control, the patient would be at risk
to start losing vision at the same rate as earlier in
the disease course, which is not desirable. Therefore,
we do not allow label downgrading for any patient
once the label upgrade is confirmed. If a patient
suspected of belonging to a higher category does
not get a confirmatory result at the very next fol-
low-up visit, then, the patient remains at the
original/lower label he/she was previously at. The
glaucoma monitoring and treatment control algo-
rithm steps are illustrated in Figure 3.
5.8. Numerical Results
In this subsection, we test the performance of our
dynamic disease monitoring and control algorithm on
glaucoma patients from the CIGTS and AGIS clinical
trials. We first validate our prediction model on the
testing dataset, using the training dataset for parame-
terization. Then, we provide numerical results and
examples on how the optimal policies behave. Lastly,
we provide further results of the impact of optimal
policies on patients with glaucoma.
5.8.1. Validation. We first validate that the model
is good at forecasting future disease progression tra-
jectory and then validate that the results are
Figure 3 Glaucoma Monitoring and Treatment Control Flow Diagram
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consistent with clinical expectations. Our modeling
approach efficiently captures the system and mea-
surement noises using a set of stochastic first-order
vector difference equations. To evaluate the perfor-
mance of our prediction model, calibrated using the
EM algorithm on the entire training set, we used the
first five data points of each patient in the testing
dataset to warm up the Kalman filter and determine
the patient type. Then, we predicted MD values for
five periods into the future for each patient type (fast-
progressor, slow-progressor, and non-progressor)
and calculated the prediction error (i.e., the predicted
state mean minus the actual reading as obtained from
the patients during their follow-up in the trial). The
predicted state mean was calculated using Kalman fil-
ter with bt ¼ 0 8t (i.e., no additional IOP reduction
beyond that in the clinical trial). Figure 4 shows the
mean MD prediction error for up to five 6-month peri-
ods (2.5 years) into the future. The dots correspond to
the mean error, and the bars represent the 95% confi-
dence interval for the mean. These interval plots con-
firm that our prediction model has very little error in
predicting the glaucoma state progression. One also
sees that the fast-progressors (as defined in subsection
5.4) vary the most in the datasets, and this is reflected
in greater uncertainty and error. However, 25 rounds
of cross-validation were performed to confirm the
robustness of our Kalman filter model to patient data.
Here, we present the results of one of the cross-valida-
tion rounds for MD, as it is the most clinically useful
state variable. Similar results were obtained for other
state elements (PSD and IOP).
5.8.2. Evaluation of the Optimal Policies.
Having confirmed that the model accurately forecasts
future MD values, we next test that the output pro-
vides clinically reasonable results as confirmed by our
clinical collaborator. The structure of optimal IOP
control generated by our model under the moderate
or high aggressiveness policy is key to identifying the
target IOP for each patient. We applied the high and
moderate aggressiveness policies to all fast- and slow-
progressing patients in the testing dataset to achieve a
statistical characterization of how each policy
behaves. For each group and each aggressiveness pol-
icy, we used the first five data points to warmup our
model. We then recorded the amount of optimal IOP
control suggested by our model in the next 20 time
Figure 4 Interval Plot of Mean MD Prediction Error for Different Prediction Lengths [Color figure can be viewed at wileyonlinelibrary.com]
Note: The dots correspond to mean error, and the bars represent 95% confidence interval for the mean.
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periods (i.e., the following 10 years). Figure 5 depicts
the results over all the patients in the testing dataset
as box plots of optimal additional IOP control (bt )
applied in the current (i.e., period 0) and the follow-
ing time periods. An IOP control of x mmHg corre-
sponds to lowering the patient’s IOP by x mmHg
more than what was achieved in AGIS/CIGTS. The
bottom and top of each box are the first and third
quartiles, respectively. The lower and upper whiskers
extend to the minimum and maximum data points
within 1.5 box heights from the bottom and top of the
box, respectively. In our model, the optimization
problem finds the optimal value for beta in each per-
iod (i.e., how much to reduce IOP in each time per-
iod). As seen in Figure 5, our feedback-driven model
recommends further lowering the IOP within the first
few time periods. Afterwards, the optimal additional
IOP control is close to zero. This results in the
patient’s IOP converging to “a number” over time.
We call this number the “target IOP,” the common
term used in the glaucoma medical community. As
one would expect, the group of non-progressing
patients do not get any additional benefit from further
lowering their IOP since they exhibit no signs of pro-
gression at the IOP levels they maintain from the
treatments already employed in the trials. Therefore,
they are not included in the graph.
We applied the five aggressiveness options to
fast- and slow-progressing patients in the test data-
set and obtained the following IOP-related metrics
for each combination of patient type and aggressive-
ness policy: (i) target IOP (mmHg), (ii) additional
IOP control (mmHg) applied in 10 years (represent-
ing the amount/intensity of treatment), and (iii)
percentage of IOP change after 10 years. For each
metric, we report the median and interquartile
range (IQR), which are robust measures of location
and scale, respectively. The IQR is the difference
between the upper and lower quartiles and pro-
vides a range that contains 50% of the data. As seen
in Figure 5, the optimal additional IOP reduction is
almost entirely applied during the first six periods
(3 years) of employing the control policy. Hence, we
evaluate the patient’s IOP after 10 years, which is a
sufficient length of time for the IOP to become
stable under treatment. We tested our IOP control
model with longer time horizons and obtained simi-
lar results.
Table 2 summarizes the IOP-related results. For
instance, applying the high aggressiveness policy to
Figure 5 Optimal IOP Controls Suggested by Our Model for Fast- and Slow-Progressing Patients Under the High and Moderate Aggressiveness Poli-
cies Over 10 Year [Color figure can be viewed at wileyonlinelibrary.com]
Note: Period 0 is the current time period (i.e., the period at which the IOP control starts).
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fast-progressors results in a median target IOP of
7.17 mmHg. This can be achieved by administering a
median additional 9.36 mmHg IOP reduction from
the baseline level of IOP attained in the trials. Such a
target IOP is, on average, 55.24% lower than the base-
line IOP (the IOP at the beginning of the 10-year pre-
diction period) of fast-progressing patients in the
trials. Since target IOP is an important metric that
helps guide the clinician in selecting the appropriate
treatment plan for the patient, the distribution of tar-
get IOPs is also given in Figure S1 in Appendix D.
Table 3 summarizes the optimal monitoring regime
for different combinations of patient type and aggres-
siveness level. For example, under the moderate
aggressiveness level, the model for slow-progressing
patients recommends measuring IOP every 6 months
and checking the visual field every 12 months. It is
worth noting that these protocols remain optimal as
long as (i) the patient follows the monitoring schedule
(i.e., does not miss a test), (ii) the patient type/label
remains unchanged, and (iii) the doctor does not
change the aggressiveness level. If any of the three cri-
teria are not met, the model modifies the monitoring
schedule to account for the missing information or
the change in patient label/aggressiveness level. The
monitoring regimes presented in Table 3 and the
range and mean of target IOPs presented in Figure S1
are clinically appropriate in the professional opinion
of our glaucoma specialist collaborator. Appendix E
estimates costs of the optimal monitoring policies.
5.8.3. Menu of Options. Now that we have vali-
dated our model and elaborated on the structure of
the optimal policies, we provide an example of how
our decision support tool can help guide clinicians in
managing a patient with glaucoma. Figure 6 depicts
the glaucoma progression trajectory (change in MD
over time) for a randomly chosen fast-progressing
patient from the AGIS trial. The figure depicts a sam-
ple output of the decision support tool (with regard to
disease control) that compares how this patient is
likely to progress over the following 10 periods
(5 years) under different aggressiveness options
defined in subsection 5.5. As demonstrated in Fig-
ure 6, the patient progresses much slower and would
have better MD values (i.e., vision quality) 5 years
into the future as the aggressiveness of IOP control is
increased. The figure provides a menu of options
related to how aggressively the doctor wants to treat
the patient, depicts the future disease progression tra-
jectory, and provides the optimal target IOP and mon-
itoring schedule for each aggressiveness option. The
doctor is then able to select the right aggressiveness
option based on evolving needs of the patient,
Table 2 Comparison of the Effect of Different Aggressiveness Options on Patient’s IOP for Fast and Slow-Progressing Patients in CIGTS and AGIS
Target IOP [mmHg]
(10-year predicted IOP)
Cumulative/Additional
IOP control [mmHg]
applied over 10 years
% of IOP change after
10 years
Median IQR Median IQR Median IQR
Fast-progressors
Super-high aggressiveness policy 6 0 10.57 4.97 64.17 9.50
High aggressiveness policy 7.17 1.70 9.36 4.17 55.24 8.76
Moderate aggressiveness policy 9.62 2.66 7.43 3.91 41.19 10.28
Low aggressiveness policy 18.45 5.69 0 0 +3.47 29.32
Super-low aggressiveness policy 22.98 6.37 +3.91 1.21 +26.53 39.23
Slow-progressors
Super-high aggressiveness policy 6 0 12.00 3.09 65.46 10.61
High aggressiveness policy 9.52 2.07 6.38 4.01 44.11 8.51
Moderate aggressiveness policy 13.08 2.02 2.13 1.52 22.69 23.29
Low aggressiveness policy 14.95 2.66 0 0 11.44 34.37
Super-low aggressiveness policy 18.66 4.24 +4.93 1.27 +11.88 43.01
Notes: Target IOP: IOP value in period 25 (i.e., 10 years into the future. Cumulative/Additional IOP control applied over 10 years:
P24
t¼5 bt . % of IOP
change after 10 years: 100 9 (Target IOP  Baseline IOP)/(Baseline IOP).
Table 3 Optimal Monitoring Regime for Different Combinations of Patient Type and Aggressiveness Level
Fast-progressors Slow-progressors Non-progressors
High aggressiveness IOP + VF every 6 months IOP + VF every 6 months IOP + VF every 12 months
Moderate aggressiveness IOP + VF every 6 months IOP every 6 months, VF every 12 months IOP every 12 months, VF
every 24 months
Low aggressiveness IOP every 6 months, VF every 12 months IOP 39 in 24 months, VF every 24 months IOP + VF every 24 months
Kazemian, Helm, Lavieri, Stein, and Van Oyen: Monitoring and Control of Glaucoma
Production and Operations Management 28(5), pp. 1082–1107, © 2018 Production and Operations Management Society 1101
adherence, health status, and other personal or clini-
cal factors.
5.8.4. Insights into Treatment Effectiveness by
Patient Type. Figure 7 graphs the average MD loss
per year against the total IOP reduction applied under
different aggressiveness policies for all fast- and slow-
progressing patients in the testing set of CIGTS and
AGIS trials. This graph provides three important
insights for managing patients with glaucoma: (i) The
curve for fast-progressors has a steeper slope, which
indicates that this group of glaucoma patients benefits
the most from further lowering of IOP from levels
attained in CIGTS/AGIS. (ii) It can be deduced from
Figure 7 that the low aggressiveness policy (point B),
which, roughly corresponds to treatment using eye
drops or laser therapy, works well enough for most
slow-progressors since the curve is fairly flat around
point B on the slow-progressors curve. In other
words, increasing the aggressiveness level from low
to moderate/high has only a minimal advantage at
preserving sight for this group of patients. This high-
lights the importance of differentiating patients by
progression type. Treating all patients similarly risks
over-treating for little gain for some patients or irre-
versible vision loss from disease progression due to
under-treating others. It can also be seen that slow-
progressors gain long-term benefits if treated under
the super-high aggressiveness policy (point E), which
often requires incisional surgery. Therefore, for slow-
progressing patients, the doctor may choose either the
low or super-high aggressiveness policy, depending
on the individual’s life expectancy, severity of glau-
coma, other personal and medical factors, and the
patient’s preferences. (iii) The steep slope of the fast-
progressors’ curve around point B indicates that
vision loss could be significantly averted (even in the
short-term) by further reduction of their IOP. Hence,
moderate, high, or super-high aggressiveness policies
(points C, D, and E on the graph, respectively) may be
more suitable for most fast-progressing glaucoma
patients and these patients often require incisional
surgery. The same result is also verified by plotting
the MD loss averted over 10 years by following the
IOP controls suggested by our model as shown in Fig-
ure S2 in Appendix D. Moreover, Table S1 in
Appendix D provides a comparison of the perfor-
mance of different IOP control options against the
low aggressiveness option for patients in our testing
dataset.
5.8.5. Sample Application of the Model in
Practice. In this subsection, we provide an illustra-
tion of how our modeling framework may be used to
Figure 6 An Example of the Trajectory of Glaucomatous Progression as Captured by Changes to MD over Time by Employing Each of the Five Different
Aggressiveness Policies for a Sample Fast-Progressing Patient from the AGIS Study [Color figure can be viewed at wileyonlinelibrary.com]
Note: Higher MD correlates with better vision quality.
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guide monitoring and control of a patient with glau-
coma. Figure 8 portrays the disease trajectory of a
sample patient. After the warmup period (i.e., the first
5 periods) the patient is initially identified as a non-
progressor. In our example, the clinician chooses the
low aggressiveness option to monitor and control the
patient. Subsequently, the model suggests taking an
IOP reading every year and a VF test every other year.
We assume the clinician and the patient follow this
protocol. The patient remains a non-progressor up to
period 13, when she becomes classified as a slow-pro-
gressor suspect. This slow-progressor status is con-
firmed after obtaining IOP and VF testing at a follow-
up visit in time period 14. When the patient becomes
a confirmed slow-progressor, for the sake of this
example, assume the doctor decides to increases the
aggressiveness level to the moderate aggressiveness
policy. Under this policy, the model recommends (i)
lowering the IOP from 24 to about 21 mmHg, (ii)
measuring the IOP every 6 months, and (iii) taking a
VF test every year. After 1.5 years (i.e., at time period
17) the doctor and patient decide to increase the
aggressiveness level further and continue care under
the high aggressiveness policy. This policy suggests
taking both IOP and VF tests every 6 months and rec-
ommends additional IOP reduction. Figure 8 also
illustrates how the patient’s glaucoma would likely
progress after period 14 if the doctor and patient had
maintained the low aggressiveness IOP control policy
during periods 5–14.
While this example relates to managing a single
patient, a few aspects should be highlighted. (i) As
described in subsection 5.7, glaucoma patients do not
always maintain the same progression rate over time.
Recall that each time a test is taken, the model
updates the MD slope estimate; hence, it is possible
that a patient moves from non-progressor status to
slow- or fast-progressor, or from slow-progressor to
fast-progressor status. (ii) As described in subsection
5.8.2, whenever the patient’s label is changed or the
clinician decides to change the aggressiveness level,
the model modifies the monitoring regime subse-
quently. (iii) As described in subsection 5.8.4, there is
little gain (in terms of preventing vision loss) in
increasing the aggressiveness level from low to high
for slow-progressing patients. Note the big gap in the
Figure 7 Average MD Loss Per Year Can Be Reduced by Applying More IOP Control [Color figure can be viewed at wileyonlinelibrary.com]
Note: Fast-progressors get more benefit from lowering their eye pressure.
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optimal IOP under the low and high aggressiveness
policies at time period 25 in Figure 8. However, this
gap results in a very small difference in the patient’s
MD values. Benefiting from this type of insight in a
busy clinic can significantly enhance the ability of
ophthalmologists and optometrists to take care of
patients with glaucoma appropriately.
6. Model Limitations and Future Work
While our modeling framework has shown great
potential in improving the monitoring and control of
patients with glaucoma, it comes with a few limita-
tions and areas for improvement. First, we only con-
sidered the IOP and VF tests in developing a
monitoring schedule for the patient, whereas there
are additional tests that can also be used to monitor
glaucomatous progression in practice. For instance, in
well-equipped clinics, optical coherence tomography
(OCT) is a non-invasive imaging test that measures
the thickness of retinal nerve fiber layer (RNFL) (see
Schuman et al. 2004). This newer testing modality
was not commercially available at the time of the
CIGTS and AGIS clinical trials on which our analysis
is based. Fortunately, the decision framework we
have developed is scalable and can easily accommo-
date quantitative measurements of tests such as OCT.
Should newer modalities for quantitatively assessing
the status of a patient’s glaucoma arise, measure-
ments from such modalities can be incorporated into
the model as well. In the future, we hope to acquire
access to other data sources which contain OCT data
and expand our state vector to accommodate data
from this testing modality.
Second, we used 6-month spaced time intervals
because CIGTS and AGIS datasets contain readings of
patient’s IOP and VF every 6 months. One can lever-
age the same modeling framework for data that is col-
lected more or less frequently (e.g., monthly or every
3 months) without loss of generality. However,
expanding our algorithm to handle unequally spaced
data automatically is another potential path for future
research.
Third, it is the case that our current approach uses
one system dynamics model for each of the three dis-
tinct patient types (i.e., fast-, slow-, and non-
Figure 8 A Non-Progressing Patient Becomes a Slow-Progressor; The Clinician Tailors Care by Increasing the Aggressiveness Level [Color figure
can be viewed at wileyonlinelibrary.com]
Notes: The first 5 periods are warmup time. From period 5 to 13, the patient is a non-progrssor, and the doctor selects the low aggressiveness policy. In
period 13, the patient becomes a slow-progressor suspect, and this label upgrade is confirmed in period 14. The doctor treats the patient under mod-
erate aggressiveness policy from period 14 to 17. In period 17, the doctor increases the aggressiveness policy to high in order to slow the progresson
rate further. Periods 14–25 show forecasted values.
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progressors). In other words, the dynamics that gov-
ern state transition are not patient specific and are not
dynamically updated with each new measurement of
MD, PSD, and IOP. It is beyond the current state of
the art to integrate Kalman filtering models with
models of uncertain dynamic changes in patient type
in an optimal manner. Fourth, our state transition
models are not designed to prevent any improvement
in disease state completely; in fact, there is a non-zero
probability that MD may increase due to the Gaussian
noise assumption (noise can take positive and nega-
tive values). In our model, the state is just an estimate
of the patient’s true state, so the state estimate may
increase or decrease (due to measurement noise) even
while the true state of the disease is continuously
declining. Nevertheless, our models still perform well
in describing an irreversible disease such as glau-
coma. This is in part because measurement noise indi-
cates that the previous state may have been mis-
measured. Thus, occasional improvement of state is
expected to be observed in the short term, but in our
model every patient will exhibit a non-increasing
trend in the long term.
Finally, future research can focus on further study-
ing the model cost parameters. In this research, we
relied on expert opinion and developed a set of cost
parameters for each aggressiveness policy that per-
formed well on our extant data. Future research, how-
ever, can try to develop algorithms to optimize the
balance between the cost of losing vision over time
from glaucoma, cost of purchasing medications/un-
dergoing surgery, cost of office visit and diagnostic
testing, anxiety and stress of undergoing glaucoma
tests, and side effects and complications of medical
and surgical therapy to lower IOP further. Also,
notice that we only considered fixed cost parameters
in this study (i.e., the effect and cost of the control is
independent of the current state variable). While the
difficulty/cost of modifying a risk factor may vary
based on the current level of the factor, we believe our
state-invariant cost assumptions to be a valid approxi-
mation of the true costs. This is confirmed by the fact
that applying the model to clinical trial patients cre-
ates control policies that are considered well within
the realm of practical treatment schemes by our glau-
coma specialist co-author. Tractable methods that
include state-dependent cost matrices would be a
welcome extension of the model.
7. Conclusions
In this study, we developed a dynamic personalized
modeling paradigm for simultaneous monitoring and
control of irreversible chronic diseases (e.g., glau-
coma). Our model incorporates each patient’s past
and present readings in a feedback-driven control
model to provide the jointly optimal solution to two
critical questions facing clinicians: (i) when to sched-
ule office visits and which suite of tests to perform to
monitor for disease progression (exploration); and (ii)
what levels of controllable disease risk factors should
be targeted to slow the rate of disease progression (ex-
ploitation). Kalman filtering methodology is built into
our modeling framework to extract noise from the
raw measurements and to estimate the disease state
in each time period optimally based on imperfect
observations. This is key to accurately identifying
genuine disease progression from testing artifacts. We
developed a multivariate continuous state space
model of disease progression and model the state
transition and the testing processes as first-order vec-
tor difference equations with multivariate Gaussian
random noises. For the new objective of minimizing
the relative change in state (i.e., disease progression),
which is imperative for managing irreversible chronic
diseases, we proved the two-way separation of opti-
mal estimation and control. This is a fundamental
finding upon which solution tractability depends. To
demonstrate the effectiveness of our approach, we
harnessed data from two landmark glaucoma ran-
domized clinical trials to parametrize and validate
our model. We showed that our Kalman filter-based
model has low error in predicting the future disease
progression trajectory. Further, we designed our deci-
sion support tool to provide a menu of options for the
clinician based on how aggressively the doctor wants
to manage the patient’s disease. For each aggressive-
ness option, the model provides for each glaucoma
patient (i) future disease progression trajectory, (ii)
optimal monitoring schedule, and (iii) optimal target
IOP. The doctor has the choice to select an appropri-
ate aggressiveness level depending on the patient’s
life expectancy, severity of glaucoma, and other per-
sonal and clinical factors. Our decision support tool
can, however, provide insight into such a selection as
discussed in Appendix C. Our numerical results
demonstrated that following the recommendations of
our model not only results in patients with better
vision quality over the treatment horizon but also
achieves significantly slower glaucoma progression
rate, which means patients will keep their sight
longer.
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